Bifogade filer
Magle Group announces allocation in the directed share issue
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
On 12 December 2024, Magle Chemoswed Holding AB ("Magle Group" or the "Company") announced that the Company's Board of Directors resolved, subject to subsequent approval by the extraordinary general meeting, on a directed issue of 887,333 shares in a total amount of approximately SEK 26.6 million (the "Directed Share Issue"). The extraordinary general meeting on 30 December 2024 resolved to approve the Directed Share Issue. The subscription price amounted to SEK 30 per share and corresponds to the subscription price in the rights issue that was announced on 22 November 2024 (the "Rights Issue") and was determined by the Board of Directors of the Company based on arm's length negotiations. The persons entitled to subscribe for shares in the Directed Share Issue were Stig Løkke Pedersen, Hans Henrik Lidgard (privately and/or through companies) and Mats Pettersson. Magle Group today, on 9 January 2025, announces that all shares in the Directed Share Issue have been subscribed for and allocated.
The investors in the Directed Share Issue have subscribed for and been allocated shares in a total approximate amount of SEK 26.6 million, corresponding to 887,333 new shares.
Out of the gross proceeds, approximately SEK 3.0 million is obtained through set-off of debts. The debts that are offset against new shares in the Directed Share Issue refer to compensation for a guarantee undertaking in connection with the Rights Issue and loans, including accrued interest.
Following registration of the Directed Share Issue with the Swedish Companies Registration Office (Sw. Bolagsverket), the Company's share capital will increase by SEK 44,366.65 through the issuance of 887,333 new shares, corresponding to a dilution effect of approximately 4.3 percent for current shareholders that have not participated in the Directed Share Issue (based on the number of shares and share capital after registration of the Rights Issue and the Directed Share Issue).
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to Magle Group in connection with the Directed Share Issue.
For enquiries, please contact:
Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0) 70 593 58 21
About Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmacept.com and www.maglebiopolymers.com.
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.